Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci 2015; 350(1): 59-62.
2. Fattore L, Fratta W. Beyond THC: The new generation of cannabinoid designer drugs. Front Behav Neurosci 2011; 5: 60.
3. Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, et al. Crystal structure of the human cannabinoid receptor CB1. Cell 2016; 167(3): 750-62.
4. Cooper ZD. Adverse effects of synthetic cannabinoids: Management of acute toxicity and withdrawal. Curr Psychiatry Rep 2016; 18(5): 52.
5. Gudsoorkar VS, Perez JA. A new differential diagnosis: synthetic cannabinoids-associated acute
renal failure. Methodist Debakey Cardiovasc J 2015; 11(3): 189-91.
6. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. Clinical features and outcomes of Takotsubo (Stress) cardiomyopathy. N Engl J Med 2015; 373(10): 929-38.
7. Tsuchihashi K, Ueshima K, Uchida T, Oh-mura N, Kimura K, Owa M, et al. Transient left ventricular apical ballooning without coronary artery stenosis: A novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J Am Coll Cardiol 2001; 38(1): 11-8.
Proof Version
Drug-induced Takotsubo Cardiomyopathy Mohammed.
Addict Health, Summer 2019; Vol 11, No 3 205
http://ahj.kmu.ac.ir, 06 July
8. Paur H, Wright PT, Sikkel MB, Tranter MH, Mansfield C, O'Gara P, et al. High levels of circulating epinephrine trigger apical cardiodepression in a beta2-adrenergic receptor/Gi-dependent manner: A new model of Takotsubo cardiomyopathy. Circulation 2012; 126(6): 697-706.
9. Ramshini E, Dabiri S, Arjmand S, Sepehri G, Khaksari M, Ahmadi-Zeidabadi M, et al. Attenuation effect of cannabinoid type 1 receptor activation on methamphetamine-induced neurodegeneration and locomotion impairments among male rats. Addict Health 2017; 9(4): 206-13.
10. Rajesh M, Batkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horvath B, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012; 61(3): 716-27.
11. Radwan MM, ElSohly MA, El-Alfy AT, Ahmed SA, Slade D, Husni AS, et al. Isolation and pharmacological evaluation of minor cannabinoids
from high-potency Cannabis sativa. J Nat Prod 2015; 78(6): 1271-6.
12. Batkai S, Pacher P. Endocannabinoids and cardiac contractile function: Pathophysiological implications. Pharmacol Res 2009; 60(2): 99-106.
13. Pacher P. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: New hopes, old concerns? Arterioscler Thromb Vasc Biol 2009; 29(1): 7-9.
14. Pacher P, Steffens S, Hasko G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: The good, the bad, and the ugly. Nat Rev Cardiol 2018; 15(3): 151-66.
15. Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: A systematic review. Eur Heart J 2006; 27(13): 1523-9.
16. Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM. Catecholamine-induced cardiomyopathy. Endocr Pract 2008; 14(9): 1137-49.
)